Ferumoxytol enhances NF-κB-responsive GBA-targeted ferroptosis gene therapy in acute myeloid leukemia
Tao Luo, Shijie Zhang, Meng Li, Kang Ding, Feng Gu · 2026
Read Ferumoxytol enhances NF-κB-responsive GBA-targeted ferroptosis gene therapy in acute myeloid leukemia by Tao Luo, Shijie Zhang, Meng Li, Kang Ding, Feng Gu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13543543.txt.
Description
Tao Luo's team published a 2026 study combining an approved iron medicine, ferumoxytol, with a gene-silencing therapy to kill acute myeloid leukaemia cells by ferroptosis, an iron-driven form of cell death. The gene target, GBA, maintains the chemistry of lysosomes, the cell's recycling compartments; blocking it leaks iron that fuels the death process. Their plasmid was designed to switch on mainly where NF-kappaB, a signalling protein overactive in this leukaemia, is already active, sparing normal cells.
In laboratory tests the iron particles amplified the silencing effect greatly, and markers plus microscopy confirmed ferroptosis as the killing route. Mice carrying the leukaemia lived significantly longer on the combination, with no obvious harm to organs, blood counts, or liver and kidney tests. Turning a tumour's own signalling addiction into the trigger for its destruction is the elegant core of the approach.
Catalog record
| CREATOR | Tao Luo, Shijie Zhang, Meng Li, Kang Ding, Feng Gu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81628 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |